Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Financings

NurExone Announces Corporate Updates

By The Northwire Desk — AI Analysis Mar 11, 2026 · 08:28 NRX · 0.58 NurExone Biologic Inc.
NRX · Price

Executive Summary

  • NurExone Biologic Inc. closed a non‑brokered private placement of 1,295,222 units at C$0.68 per unit, raising approximately $880,751 in gross proceeds.
  • Each unit includes one common share and one warrant to purchase an additional common share at C$0.85 for up to 36 months, with acceleration provisions if the TSXV price reaches C$1.70.
  • The company also announced a consulting agreement with former Bayer scientist Dr. Lars Bärfacker and its finalist status in the 2026 BOLD Awards Healthcare category.

Key Details

  • Financing Structure: 1,295,222 units; each unit = 1 common share + 1 warrant.
  • Pricing & Proceeds: C$0.68 per unit; aggregate gross proceeds ≈ $880,751 (CAD).
  • Warrant Terms: Exercise price C$0.85 per share; term 36 months from closing; acceleration possible if TSXV VWAP ≥ C$1.70 for 20 consecutive trading days, allowing expiry 30 days after notice.
  • Use of Proceeds: General working capital purposes to support pre‑clinical programs and milestone roadmap.
  • Regulatory Conditions: Closing subject to TSXV approval; securities subject to a statutory hold period of four months and one day.
  • Consulting Agreement: Dr. Lars Bärfacker (former Bayer Principal Research Scientist) engaged to advise on European scientific and strategic initiatives.
  • Award Recognition: Named finalist in the Healthcare category of the 2026 BOLD Awards; ceremony scheduled for March 27, 2026 in Barcelona, Spain.

Notable Quotes

  • “Lars brings many years of experience in the exosome field and a deep understanding of extracellular vesicle biology and its potential therapeutic applications… his perspective will be valuable as NurExone continues advancing its regenerative medicine platform globally, particularly in Europe.” – Dr. Lior Shaltiel, CEO
  • “This financing strengthens our preclinical programs and advances the Company along its milestone‑based roadmap.” – Eran Ovadya, CFO
Read the original news release →

More from NurExone Biologic Inc.

Jun 30, 2026 · 08:31

Dilutive financing at a discount underscores cash burn concerns in pre-revenue exosome developer

Financings Jun 24, 2026 · 17:01

Early-stage exosome developer secures Mexican distribution MOU while navigating a tight cash runway and going concern warning.

M&A / Property Jun 01, 2026 · 08:02

NurExone Advances Preclinical Milestones and Secures Minor Capital, But Cash Runway Narrows as Burn Rate Accelerates

Earnings May 19, 2026 · 16:04

NurExone Expands IP Portfolio with South Korea Patent Grant Amidst Manufacturing Push

Other May 14, 2026 · 16:05

NurExone’s EU Program Nod Underscores Exosome Platform’s Promise, But Cash Burn Keeps Investors on Edge

Other Apr 27, 2026 · 16:03

Patent Portfolio Expansion Masks Underlying Liquidity Constraints in Exosome Developer

M&A / Property